BioXL

WE develop innovative biopharma solutions for undertreated medical needs

Health Tech & Life Sciences

Private

Company Overview

Snapshot

Founded in October 2017, BioXL operates with 1–10 employees, focusing on biopharma solutions. The company is currently in the Pre-Funding stage, developing several innovative projects including a diagnostic test for breast cancer and an anti-cancer biologic drug for pancreatic cancer.

Business overview

BioXL is a biopharmaceutical company dedicated to developing innovative solutions for critical and underserved medical conditions. The company's core technology leverages biologicals and artificial intelligence to create products like CancerPredict, an AI-powered diagnostic test for breast cancer, CeaseCancer, an anti-cancer biologic drug for pancreatic cancer, and NES Pharma, a drug treatment to prevent or slow dementia progression. BioXL serves the healthcare and life sciences sectors, specifically targeting pharmaceuticals, and also addresses consumer demographics, including women's health and the aging population, operating within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is BioXL's primary focus in the biopharma sector?: BioXL is focused on developing innovative biopharma solutions for undertreated medical needs, including diagnostic tests and biologic drugs for various conditions.
What are some of BioXL's key product development projects?: BioXL's pivotal projects include CancerPredict, a biomarker-based diagnostic test for breast cancer; CeaseCancer, an anti-cancer biologic drug for pancreatic cancer; and NES Pharma, a drug treatment to prevent or slow dementia progression.
What technology does BioXL utilize in its CancerPredict diagnostic test?: The CancerPredict diagnostic test developed by BioXL is based on biomarkers and incorporates AI-powered software for predicting breast cancer development.
What is the mechanism of action for BioXL's CeaseCancer drug?: CeaseCancer is an anti-cancer biologic drug for pancreatic cancer that utilizes a human-recombinant version of a naturally expressed regulatory protein with a unique mechanism of action, affecting only cancer cells without harming normal cells.
What medical condition does BioXL's NES Pharma project address?: NES Pharma is a drug treatment designed to prevent or slow the progression of dementia, targeting glutamate excitotoxicity with different mechanisms of action.

External links

BioXL — full profile (machine-readable)

BioXL is a biopharma company focused on developing innovative solutions for critical and underserved medical conditions. Our pivotal portfolio projects include: CancerPredict: a diagnostic test, based on biomarker, aims to predict breast cancer development. The test planned to be integrated in the current screening program, and will be carried out by authorized labs. Product includes proprietary testing kit and AI-powered software. The project received grant from IIA (Israel Innovation Authority) CeaseCancer,: an anti-cancer biologic drug for Pancreatic cancer treatment. The product is an injectable (i.v or S.C) where the drug substance (API) is a human-recombinant version of a naturally expressed regulatory protein, having tumor suppression activity in the human body. The API has a unique MoA, affecting only cancer cells and does not harm normal cells. Efficacy and safety demonstrated in vitro and in animal models. Synergy was demonstrated with chemotherapy. The intended treatment is monotherapy or in combination with other treatments (i.e chemo or radiation)., as first line treatment or second line, where other therapies are not effective, i.e, in cases of cancer recurrence, resistant to chemotherapy. NES Pharma: drug treatment to prevent or slow dementia progression. The drug combines drug substances targeting glutamate excitotoxicity, with different MoAs, enabling efficacy with minimal adverse effects. The drug intended for subscription to people diagnosed at MCI (Mild Cognitive Impairment) or people at high risk to develop dementia. Other projects: AMP-Bio (antimicrobial drug to treat multi-drug resistant pathogens) and Marathon (delivery for use in MRT (Mitochondrial Replacement therapy))

Facts
Name	BioXL
One-liner	WE develop innovative biopharma solutions for undertreated medical needs
Type	Startup
Primary sector	Health Tech & Life Sciences
Founded	2017
Employees	1-10
Employees (exact)	4
HQ / location	Sderot, Ahavat Yisra'el St 9, Sderot, 8708719, Israel, South District
Product stage	R&D
Website	https://www.bioxlmed.com/
LinkedIn	https://www.linkedin.com/company/17876559
IL Registrar	515729630

Facts

Name

BioXL

One-liner

WE develop innovative biopharma solutions for undertreated medical needs

Type

Startup

Primary sector

Health Tech & Life Sciences

Founded

2017

Employees

1-10

Employees (exact)

HQ / location

Sderot, Ahavat Yisra'el St 9, Sderot, 8708719, Israel, South District

Product stage

R&D

Website

https://www.bioxlmed.com/

https://www.linkedin.com/company/17876559

IL Registrar

515729630

Classification
Sectors	Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development
Core technology	Biologicals, Artificial Intelligence
Target customers	Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Consumers, Demographics & Family, Women
Business models	B2B
Tags	early-detection, antibiotics, neurology, femtech, pharmaceuticals, neuroscience, cancer-therapy, cancer-diagnostics, diagnostics, elders, biopharmaceutical, microbiology, microbiome, aging-population, cancer, oncology, alzheimers-disease, women-health, targeted-cancer-therapy, anti-aging, chemotherapy

Classification

Sectors

Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development

Core technology

Biologicals, Artificial Intelligence

Target customers

Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Consumers, Demographics & Family, Women

Business models

B2B

Name	Role	Founder
Meir Azulay	CEO
Ouri Fischel	COO
Avraham Laban	CTO & Portfolio Manager

BioXL

Company Overview

Snapshot

Business overview

Company Intelligence Q&A

External links

Generate Slim Page